Maytansinoid
A maytansinoid is a chemical derivative of maytansine.[1]
Some are being investigated as the cytotoxic component of antibody-drug conjugates.[1] Anticancer properties of maytansinoids have been attributed to their ability to disrupt microtubule function. The maytaninoid emtansine (DM1), for example, binds at the ends of microtubules and thereby suppress their dynamic instability[2]
Examples:
- Ansamitocin[3]
- Mertansine/emtansine (DM1)
- ravtansine/soravtansine (DM4)
See also
- ImmunoGen Inc, developer of maytansinoid based drugs.
References
- 1 2 Chari, RV; Martell, BA; Gross, JL; et al. (January 1992). "Immunoconjugates containing novel maytansinoids: promising anticancer drugs." (PDF). Cancer Res. 52: 127–31. PMID 1727373.
- ↑ Lopus, M; Oroudjev, E; Wilson, L; Wilhelm, S; Widdison, W; Chari, R; Jordan, MA (2010). "Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules". Mol Cancer Ther. 9: 2689–99. doi:10.1158/1535-7163.MCT-10-0644. PMC 2954514
. PMID 20937594. - ↑ Yu, TW; Bai, L; Clade, D; et al. (June 2002). "The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnemapretiosum". Proc. Natl. Acad. Sci. U.S.A. 99: 7968–73. doi:10.1073/pnas.092697199. PMC 123004. PMID 12060743.
This article is issued from Wikipedia - version of the 7/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.